Current Takeaway
Rapamycin (also known as sirolimus) and other mTOR inhibitors are emerging as key therapeutic candidates for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID. The scientific rationale for these interventions centers on the hypothesis that chronic inflammation and cellular dysfunction in these post-viral and chronic illnesses are driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway. This overactivation stalls autophagy, a vital cellular cleaning and recycling process that removes damaged organelles and proteins, potentially leading to the severe energy deficits, fatigue, and post-exertional malaise (PEM) characteristic of these conditions.
Clinical translation of mTOR-inhibiting drugs focuses on restoring autophagy and alleviating core symptoms. Recent work has demonstrated that a low-dose rapamycin regimen can restore cellular autophagy and lead to significant improvements in fatigue, PEM, sleep quality, and orthostatic symptoms. Additionally, a placebo-controlled trial has been initiated to evaluate whether targeting the mTOR pathway with low-dose sirolimus can resolve underlying biological drivers and symptoms in Long COVID.
Despite these promising signals, the evidence supporting rapamycin for ME/CFS and Long COVID is in its infancy and remains highly uncertain. The only published clinical findings come from a small, uncontrolled observational pilot study, which is susceptible to placebo effects, high dropout rates, and patient-reporting biases, while the placebo-controlled trial is still actively recruiting and has not published results. Consequently, it is not yet established whether mTOR inhibitors are safe or effective for these conditions, and patients should not interpret these early research findings as clinical recommendations.
Why This Matters
Investigating rapamycin and sirolimus connects a widely discussed off-label drug to a specific, measurable cellular pathway—mTOR-mediated autophagy impairment—in post-viral and chronic fatigue syndromes. Rather than relying solely on subjective patient-reported outcomes, researchers have identified plasma biomarkers (BECLIN-1 and pSer258-ATG13) that correlate with cellular autophagy status and reflect clinical improvements. By validating a concrete biological target, this research provides a mechanistic foundation for patient symptoms like PEM and fatigue, paving the way for biomarker-guided, personalized clinical trials and the potential repurposing of existing, FDA-approved medications.
State of Evidence
- Established: Rapamycin (sirolimus) is an FDA-approved immunosuppressive drug that acts as an mTOR inhibitor, promoting cellular autophagy ex vivo and in animal models.
- Plausible but early: Low-dose rapamycin treatment correlates with self-reported symptom improvement (fatigue, PEM, orthostatic intolerance) in ME/CFS patients; clinical improvement in ME/CFS patients correlates with biomarker changes (increased BECLIN-1, decreased pSer258-ATG13) indicating restoration of the autophagy pathway.
- Not established: Low-dose rapamycin/sirolimus has not been proven safe or effective for ME/CFS or Long COVID in randomized, double-blind, placebo-controlled trials; optimal dosing, treatment duration, and long-term tolerability in these patient populations remain undefined.
- Key limitations: Published clinical evidence is limited to a single, decentralized, open-label pilot study without a control group, making it vulnerable to placebo effects; the study had a high dropout rate and used non-standardized drug formulations; the Phase 3 trial for Long COVID excludes individuals with pre-2020 ME/CFS, limiting the immediate applicability of its future findings to the wider ME/CFS community.
Timeline
2025-07-18 - Phase 3 trial registered to evaluate low-dose sirolimus for Long COVID
A Phase 3 randomized, double-blind, placebo-controlled clinical trial was registered on ClinicalTrials.gov (NCT06960928) by Dr. David Putrino at the Icahn School of Medicine at Mount Sinai to study low-dose sirolimus (rapamycin) in approximately 80 adults with Long COVID. The trial will evaluate whether inhibiting the mTOR pathway with a 12-week multi-ascending dose escalation regimen can improve patient-reported symptoms, targeting suspected cellular dysfunction, immune exhaustion, and viral persistence. This registry marks the first major placebo-controlled trial of an mTOR inhibitor in a post-viral syndrome, focusing on patients with moderate-to-severe fatigue and post-exertional malaise (PEM). However, because the trial is in the recruitment phase, it does not yet prove the efficacy or safety of sirolimus for Long COVID, nor does it establish optimal clinical dosing. Furthermore, the trial excludes participants with pre-2020 ME/CFS diagnoses, meaning its findings will not immediately prove benefits for the broader pre-pandemic ME/CFS population.
Sources:
2025-10-21 - Pilot study shows low-dose rapamycin improves symptoms and restores autophagy in ME/CFS
An open-label, uncontrolled pilot study of 86 ME/CFS patients published in the Journal of Translational Medicine showed that low-dose rapamycin (escalated to 6 mg/week) led to statistically significant reductions in core symptoms, including fatigue, post-exertional malaise (PEM), disturbed sleep, and orthostatic intolerance. Crucially, these clinical improvements correlated with plasma biomarker changes indicating a restoration of autophagy, specifically the downregulation of the inhibitory marker pSer258-ATG13 and the upregulation of the autophagy-promoting marker BECLIN-1. This development provides the first clinical evidence linking mTOR-driven autophagy impairment to ME/CFS pathophysiology and demonstrates that an existing FDA-approved drug can target this mechanism. However, as an uncontrolled observational study, it cannot prove that rapamycin caused the improvements, which remain susceptible to placebo effects and regression to the mean. Additionally, the study’s high dropout rate, reliance on self-reported questionnaires, and use of non-standardized drug formulations mean that large-scale, placebo-controlled trials are still required to confirm efficacy and safety.
Sources:
Open Questions
- What is the optimal dosing regimen of rapamycin for ME/CFS and Long COVID to maximize autophagy restoration while minimizing side effects?
- Will the clinical and biomarker improvements observed in the open-label pilot study be replicated in a rigorous, placebo-controlled randomized clinical trial?
- Does restoring autophagy translate into long-term disease modification, or does it require continuous/lifelong administration?
- Are there specific patient subgroups (e.g., defined by baseline BECLIN-1 or pSer258-ATG13 levels) who are more likely to respond to mTOR inhibition?